CYTO - Altamira Therapeutics Ltd Net earnings per share (EPS TTM)
Altamira Therapeutics (CYTO) maintains a stable image in the biotech sector based on confidence in its RNA delivery system. Growth is driven by licensing deals and the integration of Peptide+ into partner formulas. The rolling annual earnings per share on this GURU.Markets chart confirms this, where 1.81 shows the current value of the metric. Resilience to crises is guaranteed by the demand for allergy medications across any market cycle.
Summary analytical data breakdowns for Altamira Therapeutics Ltd (CYTO)
- share price and expert price forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital Altamira Therapeutics|CYTO - Long-Term Debt to Capital|Short-Term Debt to Equity Auris Medical|CYTO - Company Debts|Debt to Book Value Altamira Therapeutics Ltd.|CYTO - Amount of Long-Term Liabilities|Company Short-Term Debts Altamira Therapeutics|Quick Liquidity altamiratherapeutics.com
- net income and valuation multiples indicators:
CYTO - Net Income|Projected Future Earnings Altamira Therapeutics|CYTO - Business Payback Period|Future Price to Earnings Auris Medical|CYTO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Altamira Therapeutics Ltd.|CYTO - Operating profit EBITDA|Net earnings per share for the last 12 months Altamira Therapeutics|CYTO - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months altamiratherapeutics.com|CYTO - Net earnings per one share growth for the current year|Earnings growth forecast for next year Altamira Therapeutics
- revenue and sales proceeds data:
Fundamental company valuation:altamiratherapeutics.com - CYTO
Altamira Therapeutics (CYTO) maintains a strong position in the R&D segment through the development of peptide nanoparticles for RNA delivery. This indicator measures net income allocated per share, excluding the impact of capital structure. Investors utilize this balance to assess the real efficiency of the business prior to licensing deals with pharma behemoths. The positive trend confirms the issuer's financial stability. The annual net income per share price action reflects the company's reaction to market shocks.
Who Altamira Therapeutics competes with
HLN: Net earnings per share for the last 12 months|kenvue.com - Earnings per share for the last four quarters|VRNA: Net earnings per share (EPS TTM)|Jyong Biotech Limited - Earnings per share for the trailing year|LGND (Ligand Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Amneal Corp AMRX|Earnings per share for the last twelve months Perrigo Company plc (PRGO)|ALVO (alvotech.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) LQDA (Liquidia)|Net earnings per share (EPS TTM) Galapagos N.V. GLPG|ANIP - Earnings per share for the last twelve months|MNKD: Earnings per share for the last twelve months|AMPH (Amphastar Pharmaceuticals) - Net earnings per share for the last 12 months|PCRX: Earnings per share for the last four quarters|SPRY (ARS Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Theravance Biopharma Inc|Earnings per share for the last twelve months Aquestive Pharma (AQST)|Net earnings per share for the last 12 months scpharmaceuticals.com SCPH|Net earnings per share (EPS TTM) TECX (Tectonic Therapeutic)|Net earnings per share for the last four quarters tonixpharma.com (TNXP)|SXTC - Earnings per share for the last twelve months|Earnings per share for the trailing year EPRX (Eupraxia Pharmaceuticals)|BHST: Net earnings per share (EPS TTM)|Invizyne (EXOZ) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months ORMP|ENTX: Earnings per share for the trailing year|Net earnings per share for the last 12 months HYFT (MindWalk Holdings Inc.)|Earnings per share for the last four quarters ABVC|Net earnings per share (EPS TTM) CPIX (Cumberland Pharma)|Earnings per share for the trailing year QNTM|FibroGen, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months telomirpharma.com|ranitherapeutics.com (RANI) - Earnings per share for the last twelve months|Synergy CHC - Earnings per share for the trailing year|RLYB (Rallybio Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Lexaria|Earnings per share for the last twelve months Pulmatrix, Inc. (PULM)|PTHL: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) APM (Aptorum Group)|Lyra Therapeutics Inc. (LYRA) - Net earnings per one share for the last twelve months|IBO: Net earnings per share for the last 12 months|TNFA - Net earnings per share (EPS TTM)|YCBD (cbdmd.com) - Net earnings per share for the last 12 months|PRFX: Earnings per share for the last four quarters|LIPO (Lipella Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|OptiNose Inc (OPTN) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) PIRS|Net earnings per share for the last 12 months Procaps Group Corp PROC|Earnings per share for the last twelve months Petros Pharmaceuticals PTPI|Net earnings per share for the last four quarters qlsyy.net (QLI)|ACELYRIN - Net earnings per share (EPS TTM)|TFF Pharmaceuticals Inc. (TFFP) - Net earnings per share for the last 12 months
